Cargando…
PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models
Indoleamine 2,3-dioxygenase (IDO), which is highly expressed in human glioblastoma and involved in tumor immune escape and resistance to chemotherapy, is clinically correlated with tumor progression and poor clinical outcomes, and is a promising therapeutic target for glioblastoma. IDO inhibitors ar...
Autores principales: | Sun, Shanyue, Du, Guangying, Xue, Jiang, Ma, Jinbo, Ge, Minmin, Wang, Hongbo, Tian, Jingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047256/ https://www.ncbi.nlm.nih.gov/pubmed/29993291 http://dx.doi.org/10.1177/2058738418787991 |
Ejemplares similares
-
Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects
por: Jiang, Xue, et al.
Publicado: (2020) -
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model
por: Meng, Xiangjing, et al.
Publicado: (2017) -
Localization of Indoleamine 2,3-Dioxygenase-1 and Indoleamine 2,3-Dioxygenase-2 at the Human Maternal-Fetal Interface
por: Kudo, Yoshiki, et al.
Publicado: (2020) -
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021) -
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
por: Moon, Yong Wha, et al.
Publicado: (2015)